Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine
This article was originally published in The Pink Sheet
Executive Summary
FDA approval of Xyzal Allergy 24HR enables Sanofi to compete in the once-daily OTC pediatric antihistamine space in the US.
You may also be interested in...
Primatene Mist CRL Underscores Challenges For OTC Asthma Treatments
Second FDA complete response letter for a reformulated Primatene Mist likely pushes back by another 18 months Amphastar's potential relaunch of the OTC product after satisfying the US agency's concerns about consumers correcting using the product without a doctor’s intervention.
Pharma Firm ISO OTC Switch Partner; NDA Experience, Resources Needed
Success in OTC switches can hinge on finding the right partner, say switch consultants during a CHPA webinar. Due diligence in negotiations can help determine if a potential partner is the right fit for the time- and labor-intensive processes.
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
Merck’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.